Targeting serious diseases of immuno-inflammation and fibrosis
Tobira (NASDAQ: TBRA) is developing novel therapeutics to treat liver disease, fibrosis, and inflammatory diseases. The company's lead product, cenicriviroc, is a first-in-class dual inhibitor of CCR2 and CCR5, both of which are involved in the cycle of inflammation and fibrosis. Tobira is advancing cenicriviroc to treat non-alchoholic steatohepatitis (NASH) as one of the first immunomodulatory approaches for NASH.
